Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05059262
Registration number
NCT05059262
Ethics application status
Date submitted
17/09/2021
Date registered
28/09/2021
Date last updated
25/03/2025
Titles & IDs
Public title
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Query!
Scientific title
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
Query!
Secondary ID [1]
0
0
2024-513624-42-00
Query!
Secondary ID [2]
0
0
DCC-3014-03-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MOTION
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Tenosynovial Giant Cell Tumor
0
0
Query!
Pigmented Villonodular Synovitis
0
0
Query!
Giant Cell Tumor of Tendon Sheath
0
0
Query!
Tenosynovial Giant Cell Tumor, Diffuse
0
0
Query!
Tenosynovial Giant Cell Tumor, Localized
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bone
Query!
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vimseltinib
Treatment: Drugs - Placebo
Experimental: Part 1/Part 2 - Vimseltinib/Vimseltinib - Participants received blinded treatment of 30 mg twice a week (BIW) vimseltinib for 24 weeks in Part 1 and open-label 30 mg BIW vimseltinib in Part 2.
Placebo comparator: Part 1/Part 2: Placebo/Vimseltinib - Participants received blinded treatment of BIW matching placebo for 24 weeks in Part 1 and open-label 30 mg BIW vimseltinib in Part 2.
Treatment: Drugs: Vimseltinib
Administered orally
Treatment: Drugs: Placebo
Administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
Query!
Assessment method [1]
0
0
ORR was assessed by blinded independent radiologic review (IRR) using RECIST Version 1.1. ORR was defined as the percentage of participants who achieved either complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter (mm) in short axis. Non-nodal targets must be absent. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [1]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Secondary outcome [1]
0
0
ORR at Week 25 Per Tumor Volume Score (TVS)
Query!
Assessment method [1]
0
0
TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either CR or PR as assessed by blinded IRR using TVS. * CR: Lesion completely gone * PR: =50% decrease in volume score relative to Baseline.
Query!
Timepoint [1]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Secondary outcome [2]
0
0
Change From Baseline in Active Range of Motion (ROM) at Week 25
Query!
Assessment method [2]
0
0
Presented here is the change from baseline in active ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on active measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).
Query!
Timepoint [2]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Secondary outcome [3]
0
0
Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25
Query!
Assessment method [3]
0
0
All participants were asked 15 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." Total scores were converted to T-scores that ranged from 0 to 100, with higher scores representing less physical function interference and better health outcomes.
Query!
Timepoint [3]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Secondary outcome [4]
0
0
Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25
Query!
Assessment method [4]
0
0
The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.
Query!
Timepoint [4]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Secondary outcome [5]
0
0
Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25
Query!
Assessment method [5]
0
0
The EQ-VAS is a standardized tool for measuring overall health. EQ-VAS recorded the participant's self-rated health on a vertical VAS scale ranging from a minimum of 0 (worst imaginable health state) to a maximum of 100 (best imaginable health state). Higher scores indicated better health state.
Query!
Timepoint [5]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use
Query!
Assessment method [6]
0
0
Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine." A responder was defined as a participant who: (i) experienced a decrease of at least 30% in the mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic analgesic use.
Query!
Timepoint [6]
0
0
Baseline to Week 25 (Cycle 7, Day 1)
Query!
Eligibility
Key inclusion criteria
1. Patients =18 years of age
2. TGCT for which surgical resection is not an option (tumor biopsy to confirm diagnosis required if no histology/pathology available at screening)
3. Symptomatic disease as defined as at least moderate pain or at least moderate stiffness (defined as a score of 4 or more, with 10 describing the worst condition) within the screening period and documented in the medical record
4. Participants should complete 14 consecutive days of questionnaires during the screening period and must meet minimum requirements as outlined in study protocol
5. Must have stable analgesic regimen, as judged by the investigator, for at least 2 weeks prior to first dose of study drug
6. Must have measurable disease, as per RECIST Version 1.1, with at least one lesion having a minimum size of 2cm
7. Adequate organ and bone marrow function
8. If a female of childbearing potential, must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements
9. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures
10. Willing and able to complete the patient-reported outcome (PRO) assessments on an electronic device
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Previous use of systemic therapy (investigational or approved) targeting colony-stimulating factor 1 (CSF1) or colony-stimulating factor 1 receptor (CSF1R); previous therapy with imatinib and nilotinib is allowed
2. Received therapy for TGCT, including investigational therapy during the screening period. Participated in a non-TGCT investigational drug study within 30 days of screening.
3. Known metastatic TGCT or other active cancer that requires concurrent treatment (exceptions will be considered on a case-by-case basis)
4. QT interval corrected by Fridericia's formula (QTcF) >450 ms in males or >470 ms in females or history of long QT syndrome
5. Concurrent treatment with any study-prohibited medications
6. Major surgery within 14 days of the first dose of study drug
7. Any clinically significant comorbidities
8. Active liver or biliary disease including nonalcoholic steatohepatitis (NASH) or cirrhosis
9. Malabsorption syndrome or other illness that could affect oral absorption
10. Known active human immunodeficiency virus (HIV), acute or chronic hepatitis B, acute or chronic hepatitis C, or known active mycobacterium tuberculosis infection
11. If female, the participant is pregnant or breastfeeding
12. Known allergy or hypersensitivity to any component of the study drug
13. Contraindication to MRI
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/10/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2026
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
123
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Camperdown
Query!
Recruitment postcode(s) [1]
0
0
- Camperdown
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Washington
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Montréal
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Toronto
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Bordeaux
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Lyon
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Villejuif
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Berlin
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Essen
Query!
Country [18]
0
0
Hong Kong
Query!
State/province [18]
0
0
Hong Kong
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
Bologna
Query!
Country [20]
0
0
Italy
Query!
State/province [20]
0
0
Milan
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
Naples
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Padua
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Rome
Query!
Country [24]
0
0
Netherlands
Query!
State/province [24]
0
0
Leiden
Query!
Country [25]
0
0
Norway
Query!
State/province [25]
0
0
Oslo
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Warsaw
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Barcelona
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Madrid
Query!
Country [29]
0
0
Switzerland
Query!
State/province [29]
0
0
Basel
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Deciphera Pharmaceuticals, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05059262
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/62/NCT05059262/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/62/NCT05059262/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT05059262
Download to PDF